Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifileucel plus pembrolizumab versus pembrolizumab alone in untreated advanced melanoma
NL-OMON59369Phase 3Recruiting
- Sponsor
- Iovance Biotherapeutics
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing Lifileucel regimen plus pembrolizumab with Pembrolizumab alone (2 arms). Primary endpoint: Progression-free survival. Started Mar 2024; status: recruiting.
02
Drugs
lifileucelpembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON59369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59369.